Video

Cancer Survivors Should Discuss COVID-19 Risks with Their Health Care Providers

Expert Dr. Sara Hurvitz discusses why cancer survivors should discuss their risk factors during the COVID-19 pandemic with their healthcare providers.

The new coronavirus, also called COVID-19, is particularly concerning for patients with cancer. However, survivors, while not as immunocompromised as those in active treatment, should still discuss their risk factors with their physicians to determine what, if any, extra precautions they should take.

At the 2020 Miami Breast Cancer Conference® and Educated Patient Breast Cancer Summit, CURE® spoke with Dr. Sara Hurvitz, an associate professor of medicine at the University of California, Los Angeles, about what questions survivors should ask their medical teams to stay safe during the pandemic.

Transcription:

I don’t think that most patients who are survivors who have already been treated for their breast cancer and are not currently on chemotherapy or other therapies that lower the white (blood cell) count, they’re not necessarily at a higher risk of developing it than other patients.

But it’s important to talk to one’s oncologist and primary care physician to gauge, based on my age, based on other medical conditions that I have, or based on the medications that I’m taking, how do you gauge what my risk is, and what activities should I avoid, or what activities am I OK to do?

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Related Content